Interclass Difference in Pneumonia Risk in COPD Patients Initiating Fixed Dose Inhaled Treatment Containing Extrafine Particle Beclometasone versus Fine Particle Fluticasone
David B Price,1,2 William Henley,1,3 José Eduardo Delfini Cançado,4 Leonardo M Fabbri,5 Huib AM Kerstjens,6 Alberto Papi,7 Nicolas Roche,8 Elif Şen,9 Dave Singh,10 Claus F Vogelmeier,11 Sara Barille,12 Elena Nudo,12 Victoria Carter,1 Derek Skinner,1 Rebecca Vella,1 George Georges13 1Obser...
Main Authors: | Price DB, Henley W, Cançado JED, Fabbri LM, Kerstjens HA, Papi A, Roche N, Şen E, Singh D, Vogelmeier CF, Barille S, Nudo E, Carter V, Skinner D, Vella R, Georges G |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2022-02-01
|
Series: | International Journal of COPD |
Subjects: | |
Online Access: | https://www.dovepress.com/interclass-difference-in-pneumonia-risk-in-copd-patients-initiating-fi-peer-reviewed-fulltext-article-COPD |
Similar Items
-
Interclass Difference in Pneumonia Risk in COPD Patients Initiating Fixed Dose Inhaled Treatment Containing Extrafine Particle Beclometasone versus Fine Particle Fluticasone [Corrigendum]
by: Price DB, et al.
Published: (2022-03-01) -
Step-down from high dose fixed combination therapy in asthma patients: a randomized controlled trial
by: Papi Alberto, et al.
Published: (2012-06-01) -
Small Airways, Big Problem: Extrafine beclomethasone/formoterol in asthma and chronic obstructive pulmonary disease
by: Ashfaq Hasan, et al.
Published: (2021-01-01) -
Penggunaan Extrafine Beclometason Diproprionat/Formoterol Fumarat pada PPOK [Combined Extrafine Beclomethason Diproprionat/Formoteral Fumarat in COPD]
by: Sakinatus Syarifah, et al.
Published: (2019-05-01) -
Predictors of clinical response to extrafine and non-extrafine particle inhaled corticosteroids in smokers and ex-smokers with asthma
by: Fajri Gafar, et al.
Published: (2018-12-01)